On Friday, the U.S. Department of Health and Human Services (HHS) unveiled the selection of 15 additional drugs covered under ...

Shares of GSK PLC GSK inched up 0.78% to £13.59 Friday, on what proved to be an all-around great trading session for the ...

We recently compiled a list of the 12 Cheapest Stocks with Biggest Upside Potential. In this article, we are going to take a ...

Shares of GSK PLC GSK advanced 1.58% to £13.49 Thursday, on what proved to be an all-around favorable trading session for the ...

GSK plans five new product approvals by 2025, highlights strong specialty growth, and acquires IDRx for $1 billion to expand its oncology portfolio.

And while Wood said the pharma still isn’t interested in joining the overcrowded obesity landscape, GSK is considering ways ...

On Monday, GSK plc (GSK) stock saw a decline, ending the day at $32.7 which represents a decrease of $-0.39 or -1.18% from the prior close of $33.09. The stock opened at $32.74 and touched a low of ...

GSK Plc’s Chief Executive Officer Emma Walmsley is looking to do more deals as the British drugmaker doubles down on its return to cancer medicines.

GSK Plc CEO Emma Walmsley talks about buying US cancer biotech IDRx for as much as $1.15 billion, expanding their portfolio ...

GSK plc has agreed to acquire IDRx, a Boston-based, clinical-stage biopharmaceutical company dedicated to developing ...

(RTTNews) - British drug maker GSK plc (GSK.L, GSK) Monday announced that it has signed an agreement to acquire IDRx, a Boston-based, clinical-stage biopharmaceutical company, for up to $1.15 billion ...